glp-1 and hrt for perimenopause women, hormones can be the deciding factor on how well GLP-1s work. It turns out plus GLP-1s might be the answer. A patient came to see me in her mid-40s Perimeopausal or menopausal and wondering

Phase II Clinical Data Jastreboff 2023 (NEJM) reported 24.2% bodyweight reduction at 48 weeks - the largest effect size published for any metabolic peptide in clinical trials

Questions & Answers No published questions yet

Clin Endocrinol (Oxf) 51:787792 Backeljauw PF, Underwood LE (1996) Prolonged treatment with recombinant insulin-like growth factor-1 in children with growth hormone insensitivity syndrome a clinical research center study

Data processing: All data were acquired and processed using SCIEX OS software 2.1.0

2 Treatment groups Experimental Treatment Active Control Participants will receive 2.4 mg cagrilintide and 2.4 mg semaglutide subcutaneously once-weekly (dose escalation period of 16 weeks) for up to 84 weeks